antiviral news

Press Releases in the global landscape
Apr 9, 2024

NICE backs Veklury for treatment of COVID-19 in high-risk patients

UK health technology assessor the National Institute of Health and Care Excellence (NICE) has published final draft guidance recommending use of remdesivir for treating COVID-19 in eligible adults and children.
Read More »
Apr 8, 2024

Study uncovers consequences of molnupiravir use to treat COVID-19

A collaboration between the University of Tasmania and Royal Hobart Hospital Pathology has revealed the consequences of using molnupiravir to treat COVID-19.
Read More »
Apr 8, 2024

The Rise and Fall of Paxlovid

It’s been quite the ride for our “preferred” outpatient therapy for COVID-19, nirmatrelvir with ritonavir — much better known as Paxlovid, so allow me the license to use the licensed name.
Read More »
Apr 8, 2024

Nirmatrelvir fails to shorten COVID-19 symptoms in latest trial

A study in The New England Journal of Medicine evaluates the combination of nirmatrelvir and ritonavir against COVID-19, finding it does not significantly reduce symptom duration in vaccinated or unvaccinated adult outpatients.
Read More »
Apr 3, 2024

Paxlovid Fails to Shorten COVID in Standard-Risk and Vaccinated At-Risk Patients

Nirmatrelvir/ritonavir (Paxlovid) failed to shorten COVID-19 symptom duration among people at standard risk for severe COVID-19 and among vaccinated people with at least one risk factor for severe disease, according to final results of the phase II/III EPIC-SR trial.
Read More »
Apr 1, 2024

An effective treatment for COVID-19 is underused, research shows

A safe and effective medication designed to prevent mild-to-moderate COVID-19 infections from becoming more dangerous has been available for almost two years. But recent studies have shown many patients eligible for the drug—Paxlovid—haven't been prescribed it.
Read More »